Here are the 424B prospectus supplements from Candel Therapeutics, Inc. (CADL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CADL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CADL filings page.
Candel Therapeutics is offering 18,348,624 shares of common stock in a primary offering at a public offering price of $5.45 per share, with underwriters granted a 30-day option to purchase up to an additional 2,752,293 shares. The offering’s gross proceeds at the public offering price are shown as $100,000,000.80, with underwriting discounts of $6,000,000.05 and estimated proceeds to the company before expenses of $94,000,000.75.
The prospectus supplement discloses a related Purchase Agreement with funds managed by RTW Investments, LP under which the company would receive $100,000,000 upon FDA marketing approval of CAN-2409 for localized prostate cancer in exchange for a tiered U.S. royalty that begins at 4.67% (with a lower 1.33% tier above $1 billion in annual net sales and a capped Purchaser recovery of $250,000,000). Shares outstanding were 54,895,849 as of September 30, 2025.
Candel Therapeutics is offering $100,000,000 of its common stock. The preliminary prospectus supplement dated February 19, 2026 states the company is offering $100 million of common stock, with an underwriter option to purchase up to an additional $15 million of shares within 30 days.
The cover states the offering is of shares of common stock listed on the Nasdaq Global Market under the symbol CADL. The prospectus supplement references preliminary cash of approximately $119.7 million as of December 31, 2025 and discusses a separate Purchase Agreement providing for a conditional $100 million payment from funds managed by RTW Investments, LP upon FDA marketing approval of CAN-2409, in exchange for tiered U.S. royalties.